Methylsulfonylmethane (MSM) has shown certain potential in cancer-related research—it has been proven to regulate the cell cycle and induce apoptosis (programmed cell death) in specific cancer cells (especially breast cancer, prostate cancer, lung cancer, and liver cancer cells). This suggests that it may have the effect of slowing down cancer cell growth or enhancing the efficacy of chemotherapy.
However, it is important to note that current conclusions are only based on preliminary in vitro cell experiments (cell-level studies in a laboratory setting) and lack validation from large-scale clinical research (such as human clinical trials). Therefore, more targeted clinical studies are still needed to confirm the actual efficacy, appropriate dosage, and safety of MSM as a cancer treatment.